AF
DSGN icon

Allworth Financial’s Design Therapeutics DSGN Stock Holding History

Allworth Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38K Buy
+130
New +$1.31K ﹤0.01% 4470
2023
Q3 		– Sell
-336
Closed -$2.12K – 3464
2023
Q2 		$2.12K Buy
336
+300
+833% +$1.84K ﹤0.01% 2461
2023
Q1 		$208 Buy
+36
New +$269 ﹤0.01% 3002

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Allworth Financial's DSGN Position: Q1 2026 in Review

Allworth Financial opened a new position in Design Therapeutics (DSGN) in Q1 2026: 130 shares worth $1.38K. The stake represents ﹤0.01% of the portfolio and ranks #4470 among its holdings. This is a return to the name: Allworth Financial previously reported a position in DSGN as recently as Q2 2023.

Allworth Financial first reported a position in DSGN in Q1 2023 and has held it in 3 quarters since. The position peaked at $2.12K in Q2 2023. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Allworth Financial held 130 shares of Design Therapeutics worth $1.38K as of Q1 2026.
  • Design Therapeutics was a new Allworth Financial position in Q1 2026.
  • Design Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4470 holding.
  • Allworth Financial first reported a position in Design Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Allworth Financial's Design Therapeutics position peaked at $2.12K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.